Betterlife Pharma Insider Trading

Betterlife Pharma is a Canadian biotechnology company focused on developing and researching psychedelic compounds for mental health treatments. The company operates primarily from Vancouver, British Columbia, and conducts research activities across North America. Betterlife’s main focus areas include developing non-hallucinogenic derivatives of psychedelic compounds, particularly targeting depression, anxiety, and other mental health conditions. The company’s key projects include BETR-001, a non-hallucinogenic LSD derivative designed to treat major depressive disorder, and BETR-002, another psychedelic derivative being developed for neuropsychiatric applications. Betterlife also works on developing novel formulations and delivery methods for psychedelic medicines. The company has established partnerships with research institutions and maintains a portfolio of intellectual property related to psychedelic drug development. Betterlife was founded in 2019 and has positioned itself within the emerging psychedelic medicine sector, which has gained increased attention as traditional mental health treatments face limitations. The company conducts preclinical research and development activities while working toward advancing its compounds through regulatory approval processes for potential therapeutic use.